Celltrion, Inc. et al. v. Regeneron Pharmaceuticals, Inc. > Summary
Court Case Number IPR2023-00462
Filing Date Jan 17, 2023
Institution Decision Date Jul 20, 2023
Decision Date Feb 21, 2024
Court Patent Trial and Appeal Board
Status Terminated-Adverse Judgment
Administrative JudgesJamie T. Wisz, Susan L. C. Mitchell, John G. New
Judge Writing the Final DecisionJamie T. Wisz
Claims Challenged in the Petition: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
Claims Instituted: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
Claims Invalidated: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
Petitioner
Patent Owner
Petitioner Attorneys
10Celltrion
Attorney Name: David S. Kim
Gemini Law LLP
Celltrion
Attorney Name: Brigid M. Morris
Gemini Law LLP
Celltrion
Attorney Name: Robert Cerwinski
Gemini Law LLP
Celltrion
Attorney Name: Aviv Zalcenstein
Gemini Law LLP
Celltrion
Attorney Name: Yahn Lin Chu
Gemini Law LLP
Celltrion
Attorney Name: Ralph Tarantino
Steritech Solutions, LLC
Celltrion
Attorney Name: Lora M. Green
Gemini Law LLP
Celltrion
Attorney Name: Raymond N. Nimrod
Quinn Emanuel Urquhart & Sullivan
Celltrion
Attorney Name: Matthew A. Traupman
Quinn Emanuel Urquhart & Sullivan
Celltrion
Attorney Name: Landon A. Smith
Quinn Emanuel Urquhart & Sullivan
Patent Owner Attorneys
4Regeneron Pharmaceuticals
Attorney Name: Adam R. Brausa
Morrison & Foerster
Regeneron Pharmaceuticals
Attorney Name: Rebecca E. Weires
Morrison & Foerster
Regeneron Pharmaceuticals
Attorney Name: Kira A. Davis
Morrison & Foerster
Regeneron Pharmaceuticals
Attorney Name: Daralyn J. Durie
Morrison & Foerster
Related Patents
Doc No | Title | Issue date |
---|---|---|
10464992 | VEGF antagonist formulations suitable for intravitreal administration | Nov 5, 2019 |